Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α

Carcinogenesis

Volumn 28, Issue 3, 2007, Pages 529-536

  Shinojima, Toshiaki ^b   Oya, Mototsugu ^b   Takayanagi, Atsushi ^a   Mizuno, Ryuichi ^b   Shimizu, Nobuyoshi ^a   Murai, Masaru ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Urology ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DINUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; CPG ISLAND; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSCRIPTION; SILENCER ELEMENT; WILD TYPE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL DIVISION; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34047154015     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl143     Document Type: Article

References (41)

1. McLaughlin,J.K. and Lipworth,L. (2000) Epidemiologic aspects of renal cell cancer. Semin. Oncol., 27, 115-123.
2. Bukowski,R.M. (1997) Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer, 80, 1198-1220.
3. Yagoda,A. (1990) Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988. Prog. Clin. Biol. Res., 350, 227-241.
4. Yoshino,S., Kato,M. and Okada,K. (2000) Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res., 20, 591-594.
5. Semenza,G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
6. Harris,A.L. (2002) Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
7. Pugh,C.W. and Ratcliffe,P.J. (2003) Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med., 9, 677-684.
8. Talks,K.L., Turley,H., Gatter,K.C., Maxwell,P.H., Pugh,C.W., Ratcliffe,P.J. and Harris,A.L. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157, 411-421.
9. Yao,M., Yoshida,M., Kishida,T. et al. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst., 94, 1569-1575.
10. Sato,K., Terada,K., Sugiyama,T., Takahashi,S., Saito,M., Moriyama,M., Kakinuma,H., Suzuki,Y., Kato,M. and Kato,T. (1994) Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J. Exp. Med., 173, 355-360.
11. Jacobsen,J., Grankvist,K., Rasmuson,T. and Ljungberg,B. (2002) Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur. J. Cancer Prev., 11, 245-252.
12. Thelen,P., Hemmerlein,B., Kugler,A., Seiler,T., Ozisik,R., Kallerhoff,M. and Ringert,R.H. (1999) Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma. Anticancer Res., 19, 1563-1565.
13. Yang,J.C., Haworth,L., Sherry,R.M., Hwu,P., Schwartzentruber,D.J., Topalian,S.L., Steinberg,S.M., Chen,H.X. and Rosenberg,S.A. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 349, 427-434.
14. Wiesener,M.S., Munchenhagen,P.M., Berger,I. et al. (2001) Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res., 61, 5215-5222.
15. Na,X., Wu,G., Ryan,C.K., Schoen,S.R., di'Santagnese,P.A. and Messing,E.M. (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol., 170, 588-592.
16. Turner,K.J., Moore,J.W., Jones,A. et al. (2002) Expression of hypoxiainducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res., 62, 2957-2961.
17. Wiesener,M.S., Turley,H., Allen,W.E. et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood, 92, 2260-2268.
18. Sowter,H.M., Raval,R.R., Moore,J.W., Ratcliffe,P.J. and Harris,A.L. (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res., 63, 6130-6134.
19. Warnecke,C., Zaborowska,Z., Kurreck,J., Erdmann,V.A., Frei,U., Wiesener,M. and Eckardt,K.U. (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells.. Faseb J.
20. Kondo,K., Kico,J., Nakamura,E., Lechpammer,M. and Kaelin,W.G.,Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 1, 237-246.
21. Maranchie,J.K., Vasselli,J.R., Riss,J., Bonifacino,J.S., Linehan,W.M. and Klausner,R.D. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 1, 247-255.
22. Tachibana,M., Miyakawa,A., Nakashima,J., Murai,M., Nakamura,K., Kubo,A. and Hata,J. (2000) Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinoma line KU-19-20. Cell Tissue Res., 301, 353-367.
23. Mizuno,R., Oya,M., Shiomi,T., Marumo,K., Okada,Y. and Murai,M. (2004) Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J. Urol., 172, 723-727.
24. Ishizawa,J., Yoshida,S., Oya,M., Mizuno,R., Shinojima,T., Marumo,K. and Murai,M. (2004) Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int. J. Oncol., 25, 697-702.
25. Clark,S.J., Harrison,J., Paul,C.L. and Frommer,M. (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res., 22, 2990-2997.
26. Herman,J.G., Graff,J.R., Myohanen,S., Nelkin,B.D. and Baylin,S.B. (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA, 93, 9821-9826.
27. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
28. Maxwell,P.H., Wiesener,M.S., Chang,G.W., Clifford,S.C., Vaux,E.C., Cockman,M.E., Wykoff,C.C., Pugh,C.W., Maher,E.R. and Ratcliffe,P.J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
29. Hu,C.J., Wang,L.Y., Chodosh,L.A., Keith,B. and Simon,M.C. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell Biol., 23, 9361-9374.
30. Choi,J.W., Park,S.C., Kang,G.H., Liu,J.O. and Youn,H.D. (2004) Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Res., 64, 35-39.
31. Takai,D. and Jones,P.A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA, 99, 3740-3745.
32. Iyer,N.V., Leung,S.W. and Semenza,G.L. (1998) The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics, 52, 159-165.
33. Clark,S.J., Harrison,J. and Molloy,P.L. (1997) Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene, 195, 67-71.
34. Kondo,K., Kim,W.Y., Lechpammer,M. and Kaelin,W.G.,Jr. (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol., 1, E83.
35. Hanke,J., Brett,D., Zastrow,I., Aydin,A., Delbruck,S., Lehmann,G., Luft,F., Reich,J. and Bork,P. (1999) Alternative splicing of human genes: More the rule than the exception? Trends Genet., 15, 389-390.
36. Gothie,E., Richard,D.E., Berra,E., Pages,G. and Pouyssegur,J. (2000) Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J. Biol. Chem., 275, 6922-6927.
37. Chun,Y.S., Choi,E., Kim,T.Y., Kim,M.S. and Park,J.W. (2002) A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem. J., 362, 71-79.
38. Venables,J.P. (2004) Aberrant and alternative splicing in cancer. Cancer Res., 64, 7647-7654.
39. Raval,R.R., Lau,K.W., Tran,M.G., Sowter,H.M., Mandriota,S.J., Li,J.L., Pugh,C.W., Maxwell,P.H., Harris,A.L. and Ratcliffe,P.J. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol., 25, 5675-5686.
40. Tian,H., McKnight,S.L. and Russell,D.W. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev., 11, 72-82.
41. Ema,M., Taya,S., Yokotani,N., Sogawa,K., Matsuda,Y. and Fujii-Kuriyama,Y. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl Acad. Sci. USA, 94, 4273-4278.